In 2025, Akciju sabiedrība "BIOLAT" had revenue of 464.5 thousand EUR and loss of 27.1 thousand EUR. The company has 9 employees. Beneficial owners: Viesturs Vārpiņš.
| year | 2025Latest | 2024 | 2023 |
|---|---|---|---|
Revenue | 464,5k € +8.5% | 427,9k € +15.0% | 371,9k € -9.7% |
Profit | -27,1k € -185.0% | 31,9k € +144.2% | 13,1k € -71.8% |
Assets | 267,5k € +4.0% | 257,2k € +10.3% | 233,3k € +19.6% |
Liabilities | 90,6k € +70.4% | 53,2k € -13.0% | 61,1k € +70.2% |
Equity | 176,9k € -13.3% | 204k € +18.5% | 172,1k € +8.2% |
Employees | 9 +12.5% | 8 +14.3% | 7 +0.0% |
Overall rating | B+78/100 |
Financial health | 40/100 |
Credit history | 100/100 |
Legal history | 100/100 |
Business activity | 85/100 |
| Overall risk | Low |
No risk flags | |
No tax debts | |
Negative profit | |
Regular report filing | |
| Name, surname | Birth date | Position | Representation rights | Registered | |
|---|---|---|---|---|---|
| Board chairman | Independently |
Project count
49
Total funding
€68 933 003
EU support
€31 250 000
| Project | Period | Role | Funding received | Status |
|---|---|---|---|---|
FARMĀCIJAS, BIOMEDICĪNAS UN MEDICĪNAS TEHNOLOĢIJU KOMPETENCES CENTRS 5.1.1.2.i.0/1/22/A/CFLA/004 Program: AF | 2023. gada 30. janvāris until 2026. gada 30. jūnijs | partner | - | Līgums |
FARMĀCIJAS, BIOMEDICĪNAS UN MEDICĪNAS TEHNOLOĢIJU KOMPETENCES CENTRS 5.1.1.2.i.0/1/22/A/CFLA/004 Program: AF | 2023. gada 30. janvāris until 2026. gada 30. jūnijs | partner | - | Līgums |
FARMĀCIJAS, BIOMEDICĪNAS UN MEDICĪNAS TEHNOLOĢIJU KOMPETENCES CENTRS 5.1.1.2.i.0/1/22/A/CFLA/004 Program: AF | 2023. gada 30. janvāris until 2026. gada 30. jūnijs | partner | - | Līgums |
FARMĀCIJAS, BIOMEDICĪNAS UN MEDICĪNAS TEHNOLOĢIJU KOMPETENCES CENTRS 5.1.1.2.i.0/1/22/A/CFLA/004 Program: AF | 2023. gada 30. janvāris until 2026. gada 30. jūnijs | partner | - | Līgums |
FARMĀCIJAS, BIOMEDICĪNAS UN MEDICĪNAS TEHNOLOĢIJU KOMPETENCES CENTRS 5.1.1.2.i.0/1/22/A/CFLA/004 Program: AF | 2023. gada 30. janvāris until 2026. gada 30. jūnijs | partner | - | Līgums |
FARMĀCIJAS, BIOMEDICĪNAS UN MEDICĪNAS TEHNOLOĢIJU KOMPETENCES CENTRS 5.1.1.2.i.0/1/22/A/CFLA/004 Program: AF | 2023. gada 30. janvāris until 2026. gada 30. jūnijs | partner | - | Līgums |
FARMĀCIJAS, BIOMEDICĪNAS UN MEDICĪNAS TEHNOLOĢIJU KOMPETENCES CENTRS 5.1.1.2.i.0/1/22/A/CFLA/004 Program: AF | 2023. gada 30. janvāris until 2026. gada 30. jūnijs | partner | - | Līgums |
FARMĀCIJAS, BIOMEDICĪNAS UN MEDICĪNAS TEHNOLOĢIJU KOMPETENCES CENTRS 5.1.1.2.i.0/1/22/A/CFLA/004 Program: AF | 2023. gada 30. janvāris until 2026. gada 30. jūnijs | partner | - | Līgums |
FARMĀCIJAS, BIOMEDICĪNAS UN MEDICĪNAS TEHNOLOĢIJU KOMPETENCES CENTRS 5.1.1.2.i.0/1/22/A/CFLA/004 Program: AF | 2023. gada 30. janvāris until 2026. gada 30. jūnijs | partner | - | Līgums |
FARMĀCIJAS, BIOMEDICĪNAS UN MEDICĪNAS TEHNOLOĢIJU KOMPETENCES CENTRS 5.1.1.2.i.0/1/22/A/CFLA/004 Program: AF | 2023. gada 30. janvāris until 2026. gada 30. jūnijs | partner | - | Līgums |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
5.1.1.2.i.0/1/22/A/CFLA/004 | - | partner | - | - |
Akciju sabiedrība "BIOLAT" is located at Salaspils nov., Salaspils, Rīgas iela 111, LV-2169.
In 2025, Akciju sabiedrība "BIOLAT" had revenue of 464 473 EUR and loss of 27 127 EUR. Compared to previous year, revenue increased by 8.5%. View full financial report →
In 2024, Akciju sabiedrība "BIOLAT" had an average of 9 employees. View tax history →
The beneficial owners of Akciju sabiedrība "BIOLAT" are Viesturs Vārpiņš. View ownership details →
Yes, Akciju sabiedrība "BIOLAT" is registered as an active VAT payer with VAT number LV40003128200.
In 2024, the average gross salary at Akciju sabiedrība "BIOLAT" was approximately 1419,72 € per month (net ~ 1076,68 €). This is an approximate calculation. View salary details →
Akciju sabiedrība "BIOLAT" was founded on May 4, 1993. The company has been operating for 33 years.
| Indicator | Value | Rank | Comparison | |
|---|---|---|---|---|
Company age | 33 years | - | 0% | |
Net revenue | 464 473,00 € | - | 0% | |
Profit | -27 127,00 € | - | 0% | |
Equity | 176 907,00 € | - | 0% | |
Assets | 267 510,00 € | - | 0% | |
Fixed assets | 5900,00 € | - | 0% | |
Investments | 400,00 € | - | 0% | |
Liquidity | 2.88 | - | 75% | |
Profitability | -5.8% | - | 10% | |
Registered capital | 190 400,00 € | - | 0% |
Annual financial report for 2025.
Annual financial report for 2024.
Annual financial report for 2023.
Annual financial report for 2022.
Annual financial report for 2021.
Annual financial report for 2020.
Registered in the Latvian company register.
| Name, surname | Nationality | Birth date | |
|---|---|---|---|
| Viesturs Vārpiņš | LV |